Also, a meta-analysis confirmed that HER2 overexpression is correlated with worse overall survival among endometrial carcinoma patients and retained its adverse prognostic significance for OS even among USC patients [58]. This evidence concerns the gene ERBB2 and endometrial carcinoma.